Back to Journals » Biologics: Targets and Therapy » Volume 1 » Issue 2

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

Total article views   Abstract views HTML views PDF downloads Totals
4,530 Dovepress* 4,530 0+ 2,077 4,530
Totals 4,530 0 2,077 4,530
*Since 15 November 2007
+Since July 2016

View citations on Google Scholar